Posts Tagged ‘IOL’

How Mynosys is Gearing Up to Take on Femto

How Mynosys Is Gearing Up to Take on Femto

Now that Mynosys Cellular Devices has received FDA 510(k) clearance for its Zepto Capsulotomy System for cataract surgery, the company is planning its US launch August 1 and has partnered with Precision Lens of Bloomington, MN, to distribute the platform, Mynosys CEO John Hendrick tells OIS Weekly. Mynosys is based in Fremont, CA. Zepto takes…

Read More

Alcon Turnaround Has Novartis Exploring Spin-off

In announcing that Novartis AG is exploring spinning off its Alcon eye-care business, Novartis CEO Joseph Jimenez acknowledged that Alcon has made progress in the past year in executing its turnaround plan under CEO Mike Ball. Novartis revealed it is exploring options for Alcon that include spinning it off, issuing an IPO or keeping it,…

Read More

PowerVision’s Cheskin Delivers 20/20 Update

Barry Cheskin

Barry Cheskin, co-founder, president, and CEO of PowerVision Inc., delivers an update on the company’s next iteration of IOL, Fluidvision 2020. Cheskin tells OIS-TV the company is enrolling patients in a clinical trial to test the new IOL, which stands to provide nearly double the improvement over previous iterations. Participant: Barry Cheskin Barry Cheskin is…

Read More

Surgeons Welcome Tecnis Symfony to Grow Premium Channel

Surgeons Welcome Tecnis Symfony to Grow Premium Channel - OIS - Eye On Innovation Article - Healthegy

With the FDA’s approval last week of Abbott Medical Optics’ Tecnis Symfony IOL (intraocular lens), cataract and refractive surgeons have a new alternative to monovision correction for presbyopes that they think will give the premium IOL channel a much-needed boost. Two and a half years after scrapping plans for its Synchrony accommodating IOL in the…

Read More

Alcon Looking at looking at EDOF and IOL Technology

Michael Onuscheck, global surgical franchise head for Alcon, a Novartis company, outlined the firm’s approach to innovation within the premium channel, which involves both internal development and external partnerships and acquisitions. In this decade, the focus of cataract innovation has shifted from safety, efficacy, and efficiency/throughput to refractive outcomes and meeting patients’ expectations with respect…

Read More

Abbott Medical Optics Points to Leadership Position

Over the past year, Abbott Medical Optics (AMO) has established a leading share position in the US PC-IOL market, driven by the new low-add-power Tecnis Multifocal IOLs. Outside the US, the early success of the Tecnis Symfony Extended Range of Vision IOL has also contributed to market share gains. A large European multicenter post-market study…

Read More

Bausch + Lomb Highlights Leadership in IOLs

Bausch + Lomb, a Valeant Pharmaceuticals company, remains the only firm with an FDA-approved accommodating IOL, the Crystalens AO. Andrew Chang, general manager and senior vice president of Bausch + Lomb US Surgical, highlighted clinical data from a study of long-term quality of vision and patient satisfaction with accommodating and multifocal IOLs conducted by John…

Read More

Tom Frinzi’s Plans for AMO & Ophthalmology

Ophthalmology veteran Tom Frinzi joins OISTV to share his reasons for joining Abbott Medical Optics and what the company may be planning in coming years. Video Highlights 00:32 – What brought you to AMO? 1:20 – What are the three Ps? 2:02 – Is there a formula for leading any a company? 3:51 – How…

Read More

B&L’s Roberts Still Thinks Like a Doctor

Calvin Roberts, MD, CMO at Bausch & Lomb lends his physician’s perspective to how companies like Bausch & Lomb can serve eye care. Video Highlights 00:42 – I’m always asking what can we do for patient and what can we do for doctors? 01:00 – Think of all the things we do today for doctors…

Read More

AcuFocus Outlines Kamra Launch

The KAMRA small-aperture corneal inlay from AcuFocus was approved by the FDA in April 2015 for the treatment of presbyopia, and the company began a controlled commercial launch in June. Nicholas Tarantino, OD, chief clinical and regulatory officer of AcuFocus, said that the US rollout has exceeded every internal company metric. During the first year…

Read More

Diagnostics Here to Stay

A panel of physicians and corporate leaders discuss the increasingly important impact diagnostics have on the premium channel. Topics included number of tests done, appetite of investors and interest of corporate partners. Video Highlights 00:20 How important are preoperative diagnostics in managing the premium channel. 00:29 – Jay Pepose, MD, PhD, It’s very important. If…

Read More

CZM Focuses on “A Lot of Little Things” to Move Premium Channel

Moving cataract surgery outcomes from 80% of patients within 0.5 D of targeted refraction to 95% requires “a lot of little things,” Karlheinz Rein, PhD, vice president of cataract and retina surgery at Carl Zeiss Meditec, said during the panel on diagnostics and the premium channel at OIS@ASCRS 2016. The increased use of optical coherence…

Read More